A detailed history of Northern Trust Corp transactions in Scynexis Inc stock. As of the latest transaction made, Northern Trust Corp holds 101,052 shares of SCYX stock, worth $101,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares
101,052
Previous 102,120 1.05%
Holding current value
$101,052
Previous $204,000 26.47%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.27 - $2.23 $1,356 - $2,381
-1,068 Reduced 1.05%
101,052 $150,000
Q2 2024

Aug 14, 2024

SELL
$1.4 - $2.77 $3,178 - $6,287
-2,270 Reduced 2.17%
102,120 $204,000
Q1 2024

May 14, 2024

SELL
$1.39 - $2.21 $9,090 - $14,453
-6,540 Reduced 5.9%
104,390 $153,000
Q4 2023

Feb 13, 2024

BUY
$1.56 - $2.24 $91,603 - $131,532
58,720 Added 112.47%
110,930 $247,000
Q3 2023

Nov 13, 2023

SELL
$1.93 - $3.64 $4,267 - $8,048
-2,211 Reduced 4.06%
52,210 $119,000
Q2 2023

Aug 11, 2023

BUY
$2.38 - $3.67 $14,582 - $22,486
6,127 Added 12.69%
54,421 $160,000
Q1 2023

May 15, 2023

BUY
$1.15 - $3.0 $7,067 - $18,438
6,146 Added 14.58%
48,294 $144,000
Q3 2022

Nov 14, 2022

BUY
$1.83 - $2.93 $9,669 - $15,482
5,284 Added 14.33%
42,148 $101,000
Q2 2022

Aug 12, 2022

BUY
$1.77 - $3.87 $2,998 - $6,555
1,694 Added 4.82%
36,864 $69,000
Q1 2022

May 13, 2022

SELL
$3.56 - $6.66 $16,489 - $30,849
-4,632 Reduced 11.64%
35,170 $138,000
Q4 2021

Feb 08, 2022

BUY
$4.94 - $7.69 $12,809 - $19,940
2,593 Added 6.97%
39,802 $242,000
Q3 2021

Nov 15, 2021

BUY
$5.3 - $7.89 $14,845 - $22,099
2,801 Added 8.14%
37,209 $197,000
Q1 2021

May 12, 2021

BUY
$6.93 - $9.63 $102,369 - $142,254
14,772 Added 75.23%
34,408 $273,000
Q4 2020

Feb 11, 2021

BUY
$4.28 - $7.87 $9,022 - $16,589
2,108 Added 12.03%
19,636 $150,000
Q3 2020

Nov 16, 2020

BUY
$4.37 - $7.48 $76,597 - $131,109
17,528 New
17,528 $77,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $32.7M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.